Rescue Thrombolysis for Medium Vessel Occlusion (RESCUE-TNK)

Last updated: June 16, 2025
Sponsor: General Hospital of Shenyang Military Region
Overall Status: Completed

Phase

2/3

Condition

Cardiac Ischemia

Stroke

Thrombosis

Treatment

Tenecteplase

Clinical Study ID

NCT05657470
Y (2022) 187
  • Ages > 18
  • All Genders

Study Summary

The best reperfusion strategy for medium-sized vessel occlusion (MeVO) is not well established. Given the proven treatment effect of intra-arterial thrombolysis in patients with large vessel occlusion (LVO), the investigators hypothesized that intra-arterial tenecteplase (TNK) could increase the recanalization rate of MeVO and thus improve clinical outcome. The current study aimed to explore the safety and efficacy of intra-arterial TNK in patients with MeVO.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥18 years;

  2. Medium vessel occlusion (MeVO), referring to M2-3 of MCA; A1-3 of ACA; P1-3 of PCA;PICA, AICA or SCA (including primary, distal embolism in the same region afterthrombectomy or concurrent embolism in other regions).

  • Primary MeVO as detected by the first DSA examination or secondary MeVO aftermechanical thrombectomy for large vessel occlusion;

  • MeVO causes neurological deficits in motor strength, language, vision etc;

  • Endovascular mechanical thrombectomy cannot be performed as assessed by theinvestigator;

  • Absence of parenchymal hematoma on CT images performed in the angio suite.

  1. Within 24 hours from symptom onset;

  2. Signed informed consent by patient or patient's legally authorized representative.

Exclusion

Exclusion Criteria:

  1. Patients with completed infarction in the territory of the MeVO on non-contrast CT;

  2. Patients with intracranial hemorrhage;

  3. Coagulation disorders, tendency for systemic hemorrhagic, thrombocytopenia (<100,000/mm3);

  4. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times ofupper limit of normal value), increase in serum creatinine (more than 1.5 times ofupper limit of normal value) or requiring dialysis;

  5. After mechanical thrombectomy, severe and sustained (> 5 minutes) uncontrolledhypertension (systolic blood pressure over 180mmHg or diastolic blood pressure over 105 mmHg);

  6. Patients with contraindication or allergy to any ingredient of study medication;

  7. Pregnancy, plan to get pregnant or active lactation;

  8. The estimated life expectancy is less than 6 months due to other serious diseases;

  9. Other conditions unsuitable for this clinical study as assessed by researcher.

Study Design

Total Participants: 80
Treatment Group(s): 1
Primary Treatment: Tenecteplase
Phase: 2/3
Study Start date:
March 21, 2023
Estimated Completion Date:
June 16, 2025

Connect with a study center

  • General Hospital of Northern Theater Command

    ShenYang, 110840
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.